OUR PORTFOLIO

Oxford Nanopore
Auris Health
Potrero
BJ Bioscience
GI Windows
Exscientia
Apeiron
Boundless Bio

Collaborators

Oxford Sciences Innovation (OSI)

Based in Oxford, England, Oxford Sciences Innovation (OSI) specializes in investments in spin-outs from Oxford University’s technology, mathematical, physical, life sciences and medical sciences departments.

Oxford Nanopore Technologies

Oxford Nanopore’s goal is to enable the analysis of any living thing, by anyone,anywhere. The Company has developed the world's first and only nanopore DNA sequencing platform, which is uniquely scalable from pocket-sized formats through to ultra-high throughput devices.

Oxford Investment Consultants LLP

Oxford Investment Consultants LLP is an investment advisor that covers life sciences, healthcare and technology in the United Kingdom. The firm prefers to make investments in the University of Oxford spin out companies. Oxford Investments Consultants LLP is based in the United Kingdom.

Latest information

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance N

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHO™) companion diagnostics and expand its pipeline of novel cancer therapies targeting ecDNA.

Read more ›

Exscientia, with its World’s first AI-Designed Immuno-Oncology Drug to Enter Cli

Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 led the Series D and was joined by previous round lead investors, Novo Holdings, GT Healthcare Capital and funds managed by Blackrock. Funding from the Series D round will be used to advance Exscientia’s proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.

Read more ›